DOCSLIB.ORG

Replication Stress Leading to Apoptosis Within the S-Phase Contributes to Synergism Between Vorinostat and AZD1775 in HNSCC Harboring High Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Replication Stress Leading to Apoptosis Within the S-Phase Contributes to Synergism Between Vorinostat and AZD1775 in HNSCC Harboring High Risk Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high risk TP53 mutation Noriaki Tanaka1*, Ameeta A. Patel1*, Lin Tang1, Natalie L. Silver2, Antje Lindemann1, Hideaki Takahashi1, Roman Jaksik3, Xiayu Rao4, Nene N. Kalu5, Tseng-Cheng Chen7, Jiping Wang1, Mitchell J. Frederick8, Faye Johnson5, Frederico O. Gleber-Netto1, Siqing Fu9, Marek Kimmel3, Jing Wang4, Walter N. Hittelman6, Curtis R. Pickering1, Jeffrey N. Myers1*, Abdullah A. Osman1* *Authors contributed equally to this work 1Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Otolaryngology, Division of Head and Neck Oncologic Surgery, University of Florida College of Medicine, Gainesville, Florida. 3Department of Statistics, Rice University, Houston, Texas. 4Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer, Houston, Texas. 1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 7Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan. 8Department of Otolaryngology/Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. 9Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Funding: This work was supported by the National Institute of Health/NIDCR R01DE024601 (A.A. Osman and J.N. Myers), and The German Research Foundation (A. Lindemann). Corresponding Authors: Abdullah A. Osman, PhD, Assistant Professor, and Jeffrey N. Myers, MD, PhD, Professor of Surgery and Deputy Chair Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009 Phone: (713) 745-2667 Fax: (713) 794-4662 E-mail: [email protected]; and [email protected] Running Title: Vorinostat synergizes with AZD1775 in HNSCC Keywords: HNSCC cells, high-risk mutant p53, WEE1, AZD1775, vorinostat, DNA damage, 2 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. CDK1, Chk1, RRM2, replication stress, Rad51, homologous recombination, CD31, apoptosis Abbreviations: HNSCC, head and neck squamous cell carcinoma; CDK1, cyclin dependent kinase 1; HDACs, Histone deacetylases; RRM2, ribonucleotide reductase enzyme-2; EdU, 5- ethynyl-2-deoxyuridine; DIC, differential interference contrast; HR, homologous recombination; RPPA, Reverse phase protein array Conflicts of Interest: The authors have no potential conflicts of interest to disclose Abstract Word Count: 250 Total Number of Figures and Tables: Six Total Number of Supplementary Figures and Tables: 8 3 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: The cure rate for patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor due to resistance to standard therapy primarily consisting of chemoradiation. Since mutation of TP53 in HNSCC occurs in 60-80% of non-HPV associated cases and is in turn associated with resistance to these treatments, more effective therapies are needed. In this study, we evaluated the efficacy of a regimen combining vorinostat and AZD1775 in HNSCC cells with a variety of p53 mutations. Experimental Design: Clonogenic survival assays and an orthotopic mouse model of oral cancer were used to examine the in vitro and in vivo sensitivity of high-risk mutant p53 HNSCC cell lines to vorinostat in combination with AZD1775. Cell cycle, replication stress, homologous recombination (HR), live cell imaging, RNA-sequencing, and apoptosis analyses were performed to dissect molecular mechanisms. Results: We found that vorinostat synergizes with AZD1775 in vitro to inhibit growth of HNSCC cells harboring high-risk mutp53. These drugs interact synergistically to induce DNA damage, replication stress associated with impaired Rad51-mediated homologous recombination through activation of CDK1 and inhibition of Chk1 phosphorylation, culminating in an early apoptotic cell death during the S-phase of the cell cycle. The combination of vorinostat and AZD1775 inhibits tumor growth and angiogenesis in vivo in an orthotopic mouse model of oral cancer and prolongs animal survival. Conclusions: Vorinostat synergizes with AZD1775 in HNSCC cells with mutant p53 in vitro and in vivo. A strategy combining HDAC and WEE1 inhibition deserves further clinical investigation in patients with advanced HNSCC. 4 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relevance Although the treatment of locally advanced head and neck cancer has evolved recently, the cure rate for patients with aggressive tumors and high-risk of failure remains poor due to resistance to standard chemoradiotherapy. Since TP53, the gene that encodes the p53 protein, is by far the most commonly mutated gene found in head and neck cancer and is, in turn, associated with treatment failure and poor survival outcomes, more effective therapies are urgently needed. In this study, we evaluate the efficacy of combining the HDAC inhibitor, vorinostat, and the WEE1 inhibitor, AZD1775, in head and neck tumor cells expressing high-risk mutant p53. Our data demonstrate the vulnerability of HNSCC to vorinostat and AZD1775 through induction of replication stress associated with decreased Rad51-mediated homologous recombination. Thus, we provide preclinical foundation for initiation of clinical trials using combination of HDACs and WEE1 inhibitors particularly for patients with advanced and recurrent metastatic HNSCC tumors. 5 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide (1). The cure rate for patients with advanced HNSCC remains poor due to resistance to standard therapy primarily consisting of cisplatin and radiation. Mutation of TP53 in HNSCC occurs in 60-80% of HPV-negative cases (2,3) and is associated with resistance to these treatments. Recently, we developed a novel computational approach termed evolutionary action (EAp53), which can stratify patients with tumors harboring TP53 mutations as high or low risk. Patients with high-risk TP53 mutations had the poorest survival outcomes, shortest time to the development of distant metastases, and increased resistance to cisplatin- based therapy (4,5). Since the group of tumors with this high-risk mutations show resistance to cisplatin or radiation, we are interested in the development of novel therapeutic approaches to overcome this resistance and improve treatment outcomes. WEE1 is a kinase that has been linked to DNA damage-induced S-phase replication stress and G2/M arrest, owing to its ability to inactivate cyclin dependent kinase 1 (CDK1) through phosphorylation of the Tyr15 residue (6-10). Recently, we demonstrated that the WEE1 kinase inhibitor, AZD1775 sensitizes HNSCC cells harboring high-risk TP53 mutations to cisplatin both in vitro and in vivo through induction of persistent DNA damage response associated with mitotic delay and subsequent senescence (11). Modulation of the acetylation status of histones and transcription factors is an essential mechanism for regulating gene expression (12,13). Histone acetylation is generally associated with elevated transcription, whereas deacetylated histones are often linked to repressed transcription (14). Histone deacetylases (HDACs) act enzymatically to remove the acetyl group 6 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 8, 2017; DOI: 10.1158/1078-0432.CCR-17-0947 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. from histones and silence gene expression (14). Elevated activities of histone deacetylases
Load more

Recommended publications
  • Identification of Hub Genes Involved in the Occurrence and Development of Hepatocellular Carcinoma Via Bioinformatics Analysis
    ONCOLOGY LETTERS 20: 1695-1708, 2020 Identification of hub genes involved in the occurrence and development of hepatocellular carcinoma via bioinformatics analysis NINGNING MI1,2*, JIE CAO1-6*, JINDUO ZHANG2-5, WENKANG FU1-5, CHONGFEI HUANG1-5, LONG GAO1-5, PING YUE2-5, BING BAI2-5, YANYAN LIN1-5, WENBO MENG1-5 and XUN LI4,5,7 1The First Clinical Medical School, Lanzhou University; 2Department of Special Minimally Invasive Surgery, The First Hospital of Lanzhou University; 3Institute of Genetics, School of Basic Medical Sciences, Lanzhou University; 4Gansu Province Institute of Hepatopancreatobiliary; 5Gansu Province Key Laboratory Biotherapy and Regenerative Medicine; 6Laboratory Department; 7The Fifth Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China Received September 28, 2019; Accepted May 7, 2020 DOI: 10.3892/ol.2020.11752 Abstract. Hepatocellular carcinoma (HCC) is a heterogeneous cyclin B1 (CCNB1), cell-division cycle protein 20 (CDC20), malignancy, which is a major cause of cancer morbidity and cyclin-dependent kinase 1, BUB1 mitotic checkpoint serine/ mortality worldwide. Thus, the aim of the present study was threonine kinase β (BUB1B), cyclin A2, nucleolar and spindle to identify the hub genes and underlying pathways of HCC associated protein 1, ubiquitin‑conjugating enzyme E2 C via bioinformatics analyses. The present study screened three (UBE2C) and ZW10 interactor. Furthermore, upregulated datasets, including GSE112790, GSE84402 and GSE74656 CCNB1, CDC20, BUB1B and UBE2C expression levels from the Gene Expression Omnibus (GEO) database, and indicated worse disease-free and overall survival. Moreover, downloaded the RNA-sequencing of HCC from The Cancer a meta-analysis of tumor and healthy tissues in the Oncomine Genome Atlas (TCGA) database.
    [Show full text]
  • Biallelic TRIP13 Mutations Predispose to Wilms Tumor and Chromosome Missegregation
    Europe PMC Funders Group Author Manuscript Nat Genet. Author manuscript; available in PMC 2017 July 01. Published in final edited form as: Nat Genet. 2017 July ; 49(7): 1148–1151. doi:10.1038/ng.3883. Europe PMC Funders Author Manuscripts Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation Shawn Yost#1, Bas de Wolf#2, Sandra Hanks#1, Anna Zachariou1, Chiara Marcozzi3,4, Matthew Clarke1, Richarda de Voer2, Banafsheh Etemad2, Esther Uijttewaal2, Emma Ramsay1, Harriet Wylie1, Anna Elliott1, Susan Picton5, Audrey Smith6, Sarah Smithson7, Sheila Seal1, Elise Ruark1, Gunnar Houge8, Jonathan Pines3,4, Geert J.P.L. Kops2,9,10,+, and Nazneen Rahman1,11,+ 1Division of Genetics and Epidemiology, Institute of Cancer Research, 15 Cotswold Road, London, SM2 5NG, UK 2Hubrecht Institute – KNAW (Royal Netherlands Academy of Arts and Sciences), Uppsalalaan 8, 3584 CT Utrecht, The Netherlands 3The Gurdon Institute and Department of Zoology, University of Cambridge, Cambridge CB2 1QN, UK 4Division of Cancer Biology, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK 5Children's and Adolescent Oncology and Haematology Unit, Leeds General Infirmary, Leeds, LS1 3EX, UK 6Yorkshire Regional Clinical Genetics Service, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK 7Clinical Genetics Service, St Michael's Hospital, Southwell Street, Bristol, BS2 8EG, UK 8Center for Medical Genetics, Haukeland University Hospital, N-5021 Bergen, Norway 9Cancer Genomics Netherlands, Utrecht, The Netherlands 10Center for Molecular 11 Europe PMC Funders Author Manuscripts Medicine, University Medical Center Utrecht, 3584 CG, Utrecht, The Netherlands Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, UK SM2 5PT, UK # These authors contributed equally to this work.
    [Show full text]
  • Supplementary Data
    SUPPLEMENTARY DATA A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma Santiago Demajo et al. 1 SUPPLEMENTARY DATA INDEX Supplementary Methods p. 3 Supplementary References p. 8 Supplementary Tables (S1 to S5) p. 9 Supplementary Figures (S1 to S15) p. 17 2 SUPPLEMENTARY METHODS Western blot, immunoprecipitation, and qRT-PCR Western blot (WB) analysis was performed as previously described (1), using cyclin D1 (Santa Cruz Biotechnology, sc-753, RRID:AB_2070433) and tubulin (Sigma-Aldrich, T5168, RRID:AB_477579) antibodies. Co-immunoprecipitation assays were performed as described before (2), using cyclin D1 antibody (Santa Cruz Biotechnology, sc-8396, RRID:AB_627344) or control IgG (Santa Cruz Biotechnology, sc-2025, RRID:AB_737182) followed by protein G- magnetic beads (Invitrogen) incubation and elution with Glycine 100mM pH=2.5. Co-IP experiments were performed within five weeks after cell thawing. Cyclin D1 (Santa Cruz Biotechnology, sc-753), E2F4 (Bethyl, A302-134A, RRID:AB_1720353), FOXM1 (Santa Cruz Biotechnology, sc-502, RRID:AB_631523), and CBP (Santa Cruz Biotechnology, sc-7300, RRID:AB_626817) antibodies were used for WB detection. In figure 1A and supplementary figure S2A, the same blot was probed with cyclin D1 and tubulin antibodies by cutting the membrane. In figure 2H, cyclin D1 and CBP blots correspond to the same membrane while E2F4 and FOXM1 blots correspond to an independent membrane. Image acquisition was performed with ImageQuant LAS 4000 mini (GE Healthcare). Image processing and quantification were performed with Multi Gauge software (Fujifilm). For qRT-PCR analysis, cDNA was generated from 1 µg RNA with qScript cDNA Synthesis kit (Quantabio). qRT–PCR reaction was performed using SYBR green (Roche).
    [Show full text]
  • How Does SUMO Participate in Spindle Organization?
    cells Review How Does SUMO Participate in Spindle Organization? Ariane Abrieu * and Dimitris Liakopoulos * CRBM, CNRS UMR5237, Université de Montpellier, 1919 route de Mende, 34090 Montpellier, France * Correspondence: [email protected] (A.A.); [email protected] (D.L.) Received: 5 July 2019; Accepted: 30 July 2019; Published: 31 July 2019 Abstract: The ubiquitin-like protein SUMO is a regulator involved in most cellular mechanisms. Recent studies have discovered new modes of function for this protein. Of particular interest is the ability of SUMO to organize proteins in larger assemblies, as well as the role of SUMO-dependent ubiquitylation in their disassembly. These mechanisms have been largely described in the context of DNA repair, transcriptional regulation, or signaling, while much less is known on how SUMO facilitates organization of microtubule-dependent processes during mitosis. Remarkably however, SUMO has been known for a long time to modify kinetochore proteins, while more recently, extensive proteomic screens have identified a large number of microtubule- and spindle-associated proteins that are SUMOylated. The aim of this review is to focus on the possible role of SUMOylation in organization of the spindle and kinetochore complexes. We summarize mitotic and microtubule/spindle-associated proteins that have been identified as SUMO conjugates and present examples regarding their regulation by SUMO. Moreover, we discuss the possible contribution of SUMOylation in organization of larger protein assemblies on the spindle, as well as the role of SUMO-targeted ubiquitylation in control of kinetochore assembly and function. Finally, we propose future directions regarding the study of SUMOylation in regulation of spindle organization and examine the potential of SUMO and SUMO-mediated degradation as target for antimitotic-based therapies.
    [Show full text]
  • In Silico Analysis of Deleterious Single Nucleotide Polymorphisms in Human BUB1 Mitotic Checkpoint Serine/Threonine Kinase B Gene
    ÔØ ÅÒÙ×Ö ÔØ In silico analysis of deleterious single nucleotide polymorphisms in human BUB1 mitotic checkpoint serine/threonine kinase B gene Fatemeh Akhoundi, Nikpour Parvaneh, Emadi-Baygi Modjtaba PII: S2214-5400(16)30015-9 DOI: doi: 10.1016/j.mgene.2016.05.002 Reference: MGENE 211 To appear in: Meta Gene Received date: 23 September 2015 Revised date: 12 April 2016 Accepted date: 6 May 2016 Please cite this article as: Akhoundi, Fatemeh, Parvaneh, Nikpour, Modjtaba, Emadi- Baygi, In silico analysis of deleterious single nucleotide polymorphisms in human BUB1 mitotic checkpoint serine/threonine kinase B gene, Meta Gene (2016), doi: 10.1016/j.mgene.2016.05.002 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT In silico analysis of Deleterious Single Nucleotide Polymorphisms in Human BUB1 Mitotic Checkpoint Serine/Threonine Kinase B Gene Fatemeh Akhoundi; Nikpour Parvaneh; Emadi-Baygi Modjtaba Saman Road, Shahrekord, Chaharmahal-Bakhtiari, Iran Abstract One of the major challenges in the analysis of human genetic variation is to distinguish mutations that are functionally neutral from those that contribute to disease. BubR1 is a key protein mediating spindle-checkpoint activation that plays a role in the inhibition of the anaphase-promoting complex/cyclosome (APC/C), delaying the onset of anaphase and ensuring proper chromosome segregation.
    [Show full text]
  • Potential Sperm Contributions to the Murine Zygote Predicted by in Silico Analysis
    REPRODUCTIONRESEARCH Potential sperm contributions to the murine zygote predicted by in silico analysis Panagiotis Ntostis1,2, Deborah Carter3, David Iles1, John Huntriss1, Maria Tzetis2 and David Miller1 1Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, West Yorkshire, UK, 2Department of Medical Genetics, St. Sophia’s Children Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Attiki, Greece and 3Leeds Institute of Molecular Medicine, University of Leeds, Leeds, West Yorkshire, UK Correspondence should be addressed to D Miller; Email: [email protected] Abstract Paternal contributions to the zygote are thought to extend beyond delivery of the genome and paternal RNAs have been linked to epigenetic transgenerational inheritance in different species. In addition, sperm–egg fusion activates several downstream processes that contribute to zygote formation, including PLC zeta-mediated egg activation and maternal RNA clearance. Since a third of the preimplantation developmental period in the mouse occurs prior to the first cleavage stage, there is ample time for paternal RNAs or their encoded proteins potentially to interact and participate in early zygotic activities. To investigate this possibility, a bespoke next-generation RNA sequencing pipeline was employed for the first time to characterise and compare transcripts obtained from isolated murine sperm, MII eggs and pre-cleavage stage zygotes. Gene network analysis was then employed to identify potential interactions between paternally and maternally derived factors during the murine egg-to-zygote transition involving RNA clearance, protein clearance and post-transcriptional regulation of gene expression. Our in silico approach looked for factors in sperm, eggs and zygotes that could potentially interact co-operatively and synergisticallyp during zygote formation.
    [Show full text]
  • TALEN-Mediated Single-Base-Pair Editing Identification of an Intergenic Mutation Upstream of BUB1B As Causative Of
    TALEN-mediated single-base-pair editing identification SEE COMMENTARY of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome Hiroshi Ochiaia,b,1, Tatsuo Miyamotoa,1, Akinori Kanaic, Kosuke Hosobaa, Tetsushi Sakumab, Yoshiki Kudod, Keiko Asamie, Atsushi Ogawae, Akihiro Watanabee, Tadashi Kajiif, Takashi Yamamotob, and Shinya Matsuuraa,2 aDepartment of Genetics and Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan; bDepartment of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan; cDepartment of Molecular Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan; dDepartment of Obstetrics and Gynecology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima 734-8551, Japan; eDepartment of Pediatrics, Niigata Cancer Center Hospital, Niigata 951-8566, Japan; and fHachioji, Tokyo 192-0023, Japan Edited by Albert de la Chapelle, Ohio State University Comprehensive Cancer Center, Columbus, OH, and approved November 20, 2013 (received for review September 11, 2013) Cancer-prone syndrome of premature chromatid separation with reported monoallelic BUB1B mutations in seven Japanese families mosaic variegated aneuploidy [PCS (MVA) syndrome] is a rare au- (2), all of which had one null mutation in the first allele but no tosomal recessive disorder characterized by constitutional aneu- second mutation was found in the opposite allele despite the de- ploidy and a high risk of childhood cancer. We previously reported crease in BUB1B transcripts and a conserved BUB1B haplotype. monoallelic mutations in the BUB1B gene (encoding BUBR1) in seven The molecular basis of the second alleles was therefore unknown.
    [Show full text]
  • BUB1B Promotes Extrahepatic Cholangiocarcinoma Progression
    Jiao et al. Cell Death and Disease (2021) 12:63 https://doi.org/10.1038/s41419-020-03234-x Cell Death & Disease ARTICLE Open Access BUB1B promotes extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways Chen Yu Jiao1, Qin Chao Feng1,2, Chang Xian Li1,DongWang1,ShengHan1, Yao Dong Zhang1,WangJieJiang1, Jiang Chang1,XuehaoWang1 and Xiang Cheng Li1 Abstract Currently, the controversy regarding the expression profile and function of BUB1B in different malignancies still exist. In this project, we aimed to explore the role and molecular mechanism of BUB1B in the progression of extrahepatic cholangiocarcinoma (ECC). The expression levels of BUB1B in human ECC were evaluated by immunohistochemistry, western blot, and real-time PCR. The role and mechanism of BUB1B in CCA cell proliferation and invasion were investigated in both in vitro and in vivo functional studies. To indicate the clinical significance, a tissue microarray was performed on 113 ECC patients, followed by univariate and multivariate analyses. The expression of BUB1B was increased in both human CCA tissues and CCA cells. Results from loss-of-function and gain-of-function experiments suggested that the inhibition of BUB1B decreased the proliferation and invasiveness of CCA cells in vitro and in vivo, while overexpression of BUB1B achieved the opposite effect. Furthermore, the activation of c-Jun N-terminal kinase-c- Jun (JNK)-c-Jun pathway was regulated by BUB1B. BUB1B regulated the proliferation and invasiveness of CAA cells in a JNK-c-Jun-dependent manner. Clinically, ECC patients with BUB1B high expression had worse overall survival and recurrence-free survival than those with BUB1B low expression.
    [Show full text]
  • BUB1B Gene BUB1 Mitotic Checkpoint Serine/Threonine Kinase B
    BUB1B gene BUB1 mitotic checkpoint serine/threonine kinase B Normal Function The BUB1B gene provides instructions for making a protein called BUBR1, which is important for proper chromosome separation during cell division. Before cells divide, they must copy all of their chromosomes. The copied DNA from each chromosome is arranged into two identical structures, called sister chromatids, which are attached to one another during the early stages of cell division. The sets of chromosomes align within the cell, with each chromatid attached to a structure called a spindle microtubule; when all chromatids are correctly attached, the spindle microtubule pulls the two halves of the chromatid pair to opposite sides of the cell. The cell then divides in two such that each new cell contains one complete set of chromosomes. The BUBR1 protein helps ensure that each sister chromatid is attached to a spindle microtubule. If any chromatids remain unattached, the protein prevents cell division. Health Conditions Related to Genetic Changes Mosaic variegated aneuploidy syndrome More than a dozen mutations in the BUB1B gene have been found to cause mosaic variegated aneuploidy (MVA) syndrome type 1. This condition is characterized by cells with abnormal numbers of chromosomes, a situation known as aneuploidy. Affected individuals grow slowly and have an unusually small head size (microcephaly) and an increased risk of developing cancer in childhood. MVA syndrome type 1 occurs when both copies of the BUB1B gene have mutations. These mutations reduce the amount of BUBR1 protein in cells or impair the protein's ability to function. A shortage of functioning BUBR1 protein leads to errors in the distribution of chromatids during cell division.
    [Show full text]
  • Page 1 Exploring the Understudied Human Kinome For
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Exploring the understudied human kinome for research and therapeutic opportunities Nienke Moret1,2,*, Changchang Liu1,2,*, Benjamin M. Gyori2, John A. Bachman,2, Albert Steppi2, Rahil Taujale3, Liang-Chin Huang3, Clemens Hug2, Matt Berginski1,4,5, Shawn Gomez1,4,5, Natarajan Kannan,1,3 and Peter K. Sorger1,2,† *These authors contributed equally † Corresponding author 1The NIH Understudied Kinome Consortium 2Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, USA 3 Institute of Bioinformatics, University of Georgia, Athens, GA, 30602 USA 4 Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 5 Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC 27599, USA Key Words: kinase, human kinome, kinase inhibitors, drug discovery, cancer, cheminformatics, † Peter Sorger Warren Alpert 432 200 Longwood Avenue Harvard Medical School, Boston MA 02115 [email protected] cc: [email protected] 617-432-6901 ORCID Numbers Peter K. Sorger 0000-0002-3364-1838 Nienke Moret 0000-0001-6038-6863 Changchang Liu 0000-0003-4594-4577 Ben Gyori 0000-0001-9439-5346 John Bachman 0000-0001-6095-2466 Albert Steppi 0000-0001-5871-6245 Page 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted June 30, 2020.
    [Show full text]
  • Cell Cycle Arrest Through Indirect Transcriptional Repression by P53: I Have a DREAM
    Cell Death and Differentiation (2018) 25, 114–132 Official journal of the Cell Death Differentiation Association OPEN www.nature.com/cdd Review Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM Kurt Engeland1 Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV.Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia.
    [Show full text]
  • Expression and Prognosis Analyses of BUB1, BUB1B and BUB3 in Human Sarcoma
    www.aging-us.com AGING 2021, Vol. 13, No. 9 Research Paper Expression and prognosis analyses of BUB1, BUB1B and BUB3 in human sarcoma Zeling Long1, Tong Wu1, Qunyan Tian1, Luke A. Carlson2, Wanchun Wang1, Gen Wu1 1Department of Orthopedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China 2University of Pittsburgh, Pittsburgh, PA 15260, USA Correspondence to: Wanchun Wang, Gen Wu; email: [email protected], [email protected] Keywords: budding uninhibited by benzimidazoles, sarcoma, oncogene Received: February 4, 2021 Accepted: March 27, 2021 Published: April 19, 2021 Copyright: © 2021 Long et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Budding Uninhibited By Benzimidazoles are a group of genes encoding proteins that play central roles in spindle checkpoint during mitosis. Improper mitosis may lead to aneuploidy which is found in many types of tumors. As a key mediator in mitosis, the dysregulated expression of BUBs has been proven to be highly associated with various malignancies, such as leukemia, gastric cancer, breast cancer, and liver cancer. However, bioinformatic analysis has not been applied to explore the role of the BUBs in sarcomas. Herein, we investigate the transcriptional and survival data of BUBs in patients with sarcomas using Oncomine, Gene Expression Profiling Interactive Analysis, Cancer Cell Line Encyclopedia, Kaplan-Meier Plotter, LinkedOmics, and the Database for Annotation, Visualization and Integrated Discovery. We found that the expression levels of BUB1, BUB1B and BUB3 were higher in sarcoma samples and cell lines than in normal controls.
    [Show full text]